Summary & Overview
HCPCS Level II J3490: Unclassified Drug Administration
HCPCS Level II code J3490 represents unclassified drugs and is used to report administration of a drug or biological that lacks a specific HCPCS Level II descriptor. This catch‑all billing code is nationally important because it affects how providers document and bill for many specialty, compounded, or newly marketed therapies that have not yet been assigned unique codes. Accurate use of J3490 influences coverage determinations, claims processing, and downstream data capture for utilization and pharmacovigilance.
Key payers considered in this coverage overview include Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare. Readers will gain a concise explanation of the code’s clinical and administrative purpose, common clinical contexts in which it may appear, and related coding considerations. The publication summarizes typical sites of service, the role of unclassified drug billing in outpatient hospital settings, and comparisons to other unclassified or miscellaneous drug codes.
The content provides practical benchmarks and policy-relevant context for billing teams, practice administrators, and coding professionals, including typical service environments and the national implications of using an unclassified drug code. Where specific payer policies or claim-level details are not supplied, the text indicates that data is not available in the input.
Billing Code Overview
HCPCS Level II code J3490 is designated for unclassified drugs. It is used when an administered drug does not have a specific HCPCS Level II code and must be reported as an unclassified or miscellaneous drug.
Service Type: Drug/biological administration (HCPCS Level II)
Typical Site of Service: Outpatient Hospital (POS 22)
Data not available in the input for additional service-line details.
Clinical & Coding Specifications
Clinical Context
A patient presents to an outpatient hospital infusion center (POS 22) for administration of an unclassified injectable medication billed under HCPCS Level II code J3490. The patient has a documented history of long-term drug therapy and requires an off‑label, non‑listed, or otherwise unclassified drug preparation not captured by a specific HCPCS drug code. The ordering clinician (for example, a family medicine or internal medicine physician) documents the diagnosis and rationale in the medical record and a pharmacist or infusion nurse prepares and verifies the medication prior to administration. Drug administration is performed per facility protocols, with documentation of drug name, strength, route, total administered dose, lot number, expiration, and any discarded amount. If any portion of the vial is discarded, modifier JW is appended to J3490. If the drug administration is billed on the same date as a separate, distinct procedure, modifier 59 is used to indicate a distinct procedural service.
Coding Specifications
-
Modifiers
-
JW- Drug amount discarded/not administered to any patient: Use when a portion of a single‑use vial or dose is wasted and documentation supports the discarded amount. Append to HCPCS Level II codeJ3490when applicable. -
59- Distinct Procedural Service: Use to indicate that the service reported withJ3490is separate and distinct from other services performed on the same date of service; documentation must support separate procedural circumstances. -
Provider Taxonomies and Specialties
| Taxonomy Code | Specialty |
|---|---|
3336C0003X | Pharmacist |
207Q00000X | Family Medicine Physician |
207R00000X | Internal Medicine Physician |
-
Notes on use
-
J3490is an HCPCS Level II code for unclassified drugs used when no specific HCPCS drug code exists. -
Use of
JWrequires precise documentation of amount discarded; some payors may require separate reporting of discarded amounts per their policies. -
Use of
59requires documentation that services are distinct; some payors prefer more specific modifiers depending on payer rules.
Related Diagnoses
-
Z79.899— Other long term (current) drug therapy- Clinical relevance: Documents ongoing chronic use of medications and supports outpatient administration of an unclassified drug when the patient is receiving long‑term therapy.
-
T50.905A— Adverse effect of unspecified drugs, initial encounter- Clinical relevance: Indicates an initial encounter for an adverse drug effect; may justify administration of an alternative, unclassified drug or supportive therapy billed with
J3490during the same visit.
- Clinical relevance: Indicates an initial encounter for an adverse drug effect; may justify administration of an alternative, unclassified drug or supportive therapy billed with
-
Z51.81— Encounter for therapeutic drug level monitoring- Clinical relevance: Reflects monitoring of drug levels related to therapy; may accompany administration of an unclassified drug when therapeutic monitoring is part of the treatment plan.
Related Codes
| Code | Description |
|---|---|
J7999 | Compounded drug, not otherwise classified |
J7999is a related HCPCS Level II code for compounded drugs when no other code applies. In an outpatient hospital setting,J7999may be used for compounded preparations whileJ3490is used for unclassified single‑entity or non‑listed drug products. These codes can be alternatives depending on whether the product is a compounded formulation (J7999) or an unclassified manufactured drug (J3490). They may be reported on separate line items when both a compounded product and a non‑listed drug are administered on the same date, with appropriate modifiers to indicate distinct services.
National Reimbursement Benchmarks
National commercial averages (BUCA) have a mean rate of $89.65 compared with Medicare at $0.00 for HCPCS Level II code J3490, indicating that commercial payers report measurable mean payments while Medicare data is not present in the input. UnitedHealthcare reports the highest mean at $283.40, followed by Aetna at $115.96 and BUCA at $89.65.
Rate dispersion (P75 minus P25) is widest for UnitedHealthcare (400.00 - 75.00 = $325.00) and Aetna (147.14 - 23.30 = $123.84), reflecting broader variability in observed rates. The tightest dispersion appears for Blue Cross Blue Shield (57.45 - 37.00 = $20.45) and Cigna Health (80.00 - 55.00 = $25.00). The table and chart below present the full breakdown.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.